

Application No. 10/019,816
Filed: March 27, 2002
TC Art Unit: 1643
Confirmation No.: 9944

AMENDMENT TO THE CLAIMS

1. - 216. (Cancelled)

217. (Currently Amended) A method for inhibiting growth of a cancer cell, the method comprising:

~~providing a polypeptide comprising a cytoplasmic fragment of a β integrin subunit selected from the group consisting of $\beta 3$, $\beta 5$ and $\beta 6$, wherein the polypeptide provides a binding domain of the a β integrin subunit for ERK2 MAP kinase, and wherein said binding domain incorporates~~ comprising an amino acid linker sequence that links opposite end regions of the binding domain together, the linker sequence being non-essential for binding of the MAP kinase to said binding domain or, and the polypeptide comprising an amino acid sequence selected from the group consisting of RSKAKWQTGTNPLYR (SEQ ID No. 2), RARAKWDTANNPLYK (SEQ ID No. 22) and RSRARYDMASNPLYR (SEQ ID No. 23); and

~~providing a polypeptide having a modified amino acid sequence compared to said binding domain, wherein said modified amino acid sequence has greater than 60% amino acid sequence homology with said binding domain, binds to the MAP kinase and is other than a fragment of said β integrin subunit; and~~

~~treating a cancer cell with an effective amount of said polypeptide.~~

218. (Currently Amended) A method according to claim 217, wherein the polypeptide ~~comprises~~ consists of said binding domain for the a-ERK2 MAP kinase.

Application No. 10/019,816
Filed: March 27, 2002
TC Art Unit: 1643
Confirmation No.: 9944

219. (Currently Amended) A method according to claim 217, wherein the polypeptide comprises ~~said~~ the amino acid sequence RSKAKWQTGTNPLYR (SEQ ID No. 2) ~~modified amino acid sequence~~.

220. (Cancelled)

221. (Previously Presented) A method according to claim 217, wherein the polypeptide is coupled to a facilitator moiety that facilitates passage of the polypeptide across the outer cell membrane of the cancer cell into the cytoplasm of the cancer cell.

222-224. (Cancelled)

225. (Previously Presented) A method according to claim 217 wherein the cancer cell is a colon cancer cell.

226-237. (Cancelled)

238. (Previously Presented) A method according to claim 217, wherein the cancer cell is a cancer cell of a cancer selected from the group consisting of cancer of the lip, tongue, salivary glands, gums, floor and other areas of the mouth, oropharynx, nasopharynx, hypopharynx and other oral cavities, oesophagus, stomach, small intestine, duodenum, colon, rectum, gallbladder, pancreas, larynx, trachea, bronchus, lung, breast, uterus, cervix, ovary, vagina, vulva, prostate, testes, penis, bladder, kidney, thyroid and skin.

239-276. (Cancelled)

Application No. 10/019,816
Filed: March 27, 2002
TC Art Unit: 1643
Confirmation No.: 9944

277. (Previously Presented) A method according to claim 217, wherein the polypeptide is between about 5 amino acids and about 25 amino acids in length.

278-282. (Cancelled)

283. (New) A method according to claim 277 wherein the polypeptide is 10 amino acids or 15 amino acids in length.

284. (New) The method of claim 217, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of RSKAKWQTGTNPLYR (SEQ ID No. 2), RARAKWDTANNPLYK (SEQ ID No. 22) and RSRARYDMASNPLYR (SEQ ID No. 23), from which amino acid sequence said non-essential amino acid linker sequence has been deleted.

285. (New) The method of claim 284, wherein said polypeptide comprises the amino acid sequence RSKAKNPLYR (SEQ ID No. 3).